Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative chemoradiation with or without panitumumab for high-risk resected head and neck squamous cell carcinoma
2008-006180-36Phase 3Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Aug 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of panitumumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Disease-free survival. Started Aug 2010; status: terminated.
02
Drugs
panitumumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2008-006180-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006180-36.